A serum free light chain test measures free kappa (κ) and free lambda (λ) immunoglobulin light chains in the blood and calculates the kappa-to-lambda ratio. Plasma cells normally make small amounts of free light chains in addition to complete antibodies, and the kidneys clear much of this protein from the circulation. When one clone of plasma cells grows abnormally, it may produce a large excess of one light-chain type, causing the involved light chain to rise and the ratio to become abnormal. That pattern can help detect or monitor multiple myeloma, light-chain myeloma, monoclonal gammopathy of undetermined significance (MGUS), AL amyloidosis, and other monoclonal gammopathies. The test is sensitive, but it is not specific for cancer. Kidney disease, inflammation, infection, and differences between laboratory assays can raise free light-chain concentrations. The most useful interpretation combines the absolute kappa and lambda levels, their ratio, kidney function, serum protein electrophoresis, immunofixation, symptoms, and—when needed—bone marrow and imaging findings.
- The key result is usually the kappa/lambda ratio, not a high kappa or lambda level by itself. A markedly skewed ratio suggests monoclonal production more strongly than proportional elevation of both chains.
- A common standard reference ratio is about 0.26–1.65, but the correct range depends on the assay and kidney function. Use the laboratory’s own reference interval.
- Kidney impairment often raises both kappa and lambda levels and can widen the expected ratio, so standard ranges may create false-positive results in chronic kidney disease.
- In multiple myeloma, an involved/uninvolved free light-chain ratio of 100 or more can be a myeloma-defining biomarker only when additional criteria are met, including a sufficiently high involved light-chain concentration and current diagnostic requirements.
- An abnormal free light-chain result does not diagnose myeloma on its own. SPEP, immunofixation, blood counts, kidney function, calcium, bone marrow, and imaging may be needed.
Table of Contents
- What Free Light Chains Are
- What the Serum Free Light Chain Test Measures
- Normal Ranges and Kidney Function
- How to Interpret High, Low, and Abnormal Results
- Free Light Chains in MGUS, Myeloma, and Amyloidosis
- Using Free Light Chains for Monitoring
- Limitations, Preparation, and Next Steps
What Free Light Chains Are
Antibodies, also called immunoglobulins, are proteins made by plasma cells. Each complete antibody contains two heavy chains and two light chains. The light-chain portion is either kappa or lambda.
Plasma cells normally make a little more light-chain material than they need to assemble full antibodies. These unattached pieces circulate as free light chains (FLCs). Healthy people therefore have measurable free kappa and free lambda in the blood.
A normal immune system contains many different plasma-cell clones. Because both kappa-producing and lambda-producing cells are present, the balance between the two free light-chain types stays within a predictable range. A monoclonal plasma-cell disorder changes that balance. If one abnormal clone produces kappa, free kappa may rise disproportionately and the kappa/lambda ratio shifts upward. If the clone produces lambda, the ratio may fall.
This distinction is important because both kappa and lambda can be high without a monoclonal disorder. Chronic kidney disease reduces clearance of free light chains. Inflammation can stimulate many plasma-cell clones at once. In those settings, both light-chain concentrations may increase while the ratio remains relatively balanced.
The serum FLC assay is part of the standard laboratory evaluation for many plasma-cell disorders and is usually interpreted alongside serum protein electrophoresis (SPEP) and serum immunofixation.
What the Serum Free Light Chain Test Measures
A typical report includes three core values:
- Free kappa light chains, usually reported in mg/L.
- Free lambda light chains, usually reported in mg/L.
- Kappa/lambda ratio, calculated from the two concentrations.
The report may also identify the involved and uninvolved light chain. The involved light chain is the type produced by the abnormal clone; the uninvolved light chain is the opposite type. In kappa myeloma, for example, kappa is involved and lambda is uninvolved.
Clinicians sometimes calculate the difference between involved and uninvolved free light chains (dFLC). This value is particularly useful in conditions such as AL amyloidosis and in some patients whose disease cannot be measured reliably by an M-spike on electrophoresis.
The test uses antibodies that recognize free light-chain structures not normally exposed when the light chain is attached to a heavy chain. Different manufacturers use different reagents and calibration systems. As a result, absolute values and reference ranges can differ between platforms.
That leads to a practical rule: serial results are easiest to interpret when the same assay and laboratory are used. Switching platforms can create an apparent change that reflects methodology rather than biology.
Blood is the usual specimen. No bone marrow is needed for the serum FLC measurement itself. The test may be ordered as part of a multiple myeloma test panel when a monoclonal plasma-cell disorder is suspected.
Normal Ranges and Kidney Function
Many laboratories using the traditional Freelite assay have historically used approximate reference intervals of 3.3–19.4 mg/L for kappa, 5.7–26.3 mg/L for lambda, and 0.26–1.65 for the kappa/lambda ratio. These values are not universal. The report from the laboratory that performed the test should take priority.
Kidney function can substantially change the expected numbers. Free light chains are filtered and metabolized by the kidneys, so concentrations rise as kidney function declines. Both kappa and lambda can become markedly elevated in chronic kidney disease even when no plasma-cell clone is present.
Large population studies have shown that using one “renal range” for everyone with reduced kidney function can still misclassify many people. More refined ranges based on estimated glomerular filtration rate (eGFR) have been proposed. For example, the iStopMM study proposed broader kappa/lambda ratio intervals as eGFR fell, with different ranges for eGFR 45–59, 30–44, and below 30 mL/min/1.73 m².
This does not mean every laboratory has adopted those exact intervals. Assay platform, validation method, population, and local laboratory policy matter. A clinician interpreting an abnormal result should check:
- the assay-specific reference range;
- creatinine and eGFR;
- whether the patient is on dialysis;
- whether both light chains rose proportionally;
- whether SPEP or immunofixation shows a monoclonal protein.
Newer research has also suggested that conventional reference intervals may be too narrow in some people with preserved kidney function, particularly by age and assay. This is an evolving area, so a slightly abnormal ratio near the cutoff should be interpreted much more cautiously than an extreme ratio with a large involved light-chain elevation.
How to Interpret High, Low, and Abnormal Results
The pattern is more important than any isolated number.
| Pattern | Common interpretation | What else matters |
|---|---|---|
| Kappa high, ratio high | Possible kappa monoclonal process | Degree of ratio skew, kidney function, SPEP/IFE, symptoms |
| Lambda high, ratio low | Possible lambda monoclonal process | Degree of ratio skew, kidney function, SPEP/IFE, symptoms |
| Kappa and lambda both high, ratio near expected range | Often reduced renal clearance or polyclonal immune activation | eGFR, infection, inflammation, liver/immune disease |
| One light chain markedly high with extreme ratio | Stronger evidence for monoclonal production | Myeloma criteria, marrow, imaging, organ damage |
| Both low | Reduced immunoglobulin production or treatment effect may be possible | Total immunoglobulins, therapy, immune status |
A mildly abnormal ratio does not have the same meaning as a ratio of 20, 100, or several hundred. The farther the ratio moves from the expected range—and the higher the involved free light chain—the more strongly a clonal process may be suspected, assuming kidney function and assay issues do not explain the finding.
Inflammation and infection can raise polyclonal free light chains. Autoimmune disease and chronic liver disease can do the same. These conditions usually raise both chains rather than creating a large, stable imbalance.
Kidney failure creates a common diagnostic trap. A patient may have kappa of 80 mg/L and lambda of 60 mg/L, both far above a standard healthy reference range, yet the ratio may remain close to 1.3. That pattern is very different from kappa 800 mg/L, lambda 10 mg/L, and a ratio of 80.
Even an extreme ratio is not interpreted without clinical context. Multiple myeloma diagnosis requires evidence of a clonal plasma-cell disorder plus a myeloma-defining event, not simply one abnormal blood test.
Free Light Chains in MGUS, Myeloma, and Amyloidosis
MGUS
MGUS is a precursor condition in which a monoclonal protein or clonal plasma-cell population is present without myeloma-defining organ damage or other criteria requiring treatment. An abnormal FLC ratio is one of the factors used to estimate progression risk in conventional MGUS.
In light-chain MGUS, the abnormal clone produces free light chains without a detectable intact immunoglobulin M-protein. Diagnosis requires careful exclusion of myeloma, AL amyloidosis, kidney disease-related distortion, and other causes. New population data have prompted proposals for updated FLC reference intervals and definitions to reduce overdiagnosis.
Multiple myeloma
Free light chains have several roles in myeloma. They can help detect disease, establish prognosis, and monitor patients whose tumor secretes mainly or only light chains.
A very abnormal involved/uninvolved FLC ratio is also part of myeloma diagnostic criteria. An involved/uninvolved ratio of at least 100, together with an involved FLC concentration of at least 100 mg/L and the other required diagnostic conditions, can qualify as a myeloma-defining biomarker in current frameworks. Contemporary guidance also emphasizes the entire clinical picture, including urine monoclonal protein and other evidence, because risk is not identical in every patient who crosses the ratio threshold.
This criterion was designed to identify some patients at sufficiently high risk of progression or organ injury that waiting for classic CRAB features—hypercalcemia, renal failure, anemia, or bone lesions—would be unsafe.
AL amyloidosis and light-chain deposition disease
In AL amyloidosis, an abnormal plasma-cell clone makes light chains that misfold and deposit in organs such as the heart, kidneys, nerves, liver, or gastrointestinal tract. The difference between involved and uninvolved FLCs is often used to quantify the clone and assess hematologic response.
Small plasma-cell clones can cause serious organ disease in AL amyloidosis, so a modest M-spike does not necessarily mean the condition is minor. Symptoms such as unexplained heart failure, nephrotic-range proteinuria, neuropathy, enlarged tongue, easy bruising around the eyes, or autonomic dysfunction may prompt a more targeted evaluation.
Using Free Light Chains for Monitoring
Serum FLC testing can change quickly because free light chains have a relatively short half-life. That makes the test useful for tracking rapidly changing disease burden in light-chain myeloma and AL amyloidosis.
The test is especially valuable when SPEP cannot quantify a clear M-spike. Examples include:
- light-chain-only myeloma;
- oligosecretory myeloma;
- some previously labeled “nonsecretory” myeloma cases;
- AL amyloidosis;
- selected monoclonal gammopathies with low intact immunoglobulin production.
For patients with a clearly measurable intact immunoglobulin M-protein, SPEP remains an important monitoring tool. FLC can provide complementary information, but a small day-to-day change should not automatically be called progression.
Clinicians look for sustained patterns that fit established response criteria. A falling involved light chain and improving ratio may indicate treatment response. A confirmed rise can suggest biochemical progression, especially when it occurs with a rising M-protein, worsening blood counts, kidney injury, new bone pain, or other evidence of disease activity.
Treatment itself can temporarily alter immunoglobulin production. Modern therapies may suppress normal plasma cells as well as malignant ones, changing the uninvolved light chain and therefore the ratio. This is another reason to interpret the ratio together with the absolute involved FLC and the broader response assessment.
For myeloma follow-up, FLC results are often combined with SPEP, immunofixation, complete blood count, calcium, creatinine, quantitative immunoglobulins, and imaging or marrow studies when indicated. Deeper response can be assessed with myeloma MRD testing, which measures residual clonal plasma cells rather than serum protein secretion.
Limitations, Preparation, and Next Steps
The serum free light-chain test is a powerful marker, but it has several limitations.
Assays are not interchangeable. Different commercial tests can produce different kappa, lambda, and ratio values from the same specimen. A reference range belongs to the assay that generated it.
Kidney disease complicates interpretation. Reduced filtration raises FLC concentrations, and dialysis can affect levels. A mild ratio abnormality in CKD is much less specific than a strongly skewed ratio with a dominant involved chain.
Antigen excess can rarely distort immunoassays. Very high concentrations may produce nonlinearity or unexpectedly low measurements if the assay does not adequately detect the excess. Laboratories use dilution and quality-control procedures to reduce this problem, but an implausible result should be questioned.
A normal FLC ratio does not exclude every monoclonal gammopathy. Intact immunoglobulin MGUS or myeloma can produce a clear M-protein with a ratio that is not dramatically abnormal. This is why FLC should not replace SPEP and immunofixation when a monoclonal protein is being investigated.
No fasting is usually required. Dehydration can affect kidney-related laboratory values, so following normal hydration instructions is reasonable unless a clinician has advised fluid restriction.
If a result is abnormal, common next steps include repeat testing, SPEP, immunofixation, quantitative immunoglobulins, creatinine/eGFR, calcium, complete blood count, and urine studies. Depending on the degree of abnormality and symptoms, a hematologist may recommend bone marrow biopsy and imaging.
A beta-2 microglobulin test may also be used in established myeloma for staging and prognosis, but it answers a different question and is strongly influenced by kidney function.
Seek prompt medical evaluation for severe weakness, confusion, dehydration, reduced urine output, new severe bone pain, rapidly worsening shortness of breath, or symptoms of high calcium or kidney injury. The FLC number itself is not an emergency threshold; urgency depends on the clinical problem behind it.
Serial free light chain results are most reliable when the same assay and laboratory are used. Different commercial methods can produce different absolute kappa, lambda, and ratio values, especially at very high concentrations. A sudden change that does not match the clinical course may therefore need confirmation before it is interpreted as progression or response.
Very high free light chain concentrations can also create analytical problems such as antigen excess, sometimes called a hook effect, in which an undiluted sample can underestimate the true level. Modern laboratories use dilution checks and assay safeguards, but clinicians may ask for repeat analysis when the result seems unexpectedly low compared with urine protein, kidney injury, or known disease burden.
The ratio should always be read with the absolute involved light chain. A mildly abnormal ratio caused by reduced kidney clearance is very different from an extreme ratio accompanied by a markedly increased involved kappa or lambda concentration. Clinicians therefore avoid interpreting the ratio as a stand-alone cancer score.
References
- Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management 2026 (Review)
- Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review 2025 (Review)
- New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance 2025
- Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies 2023 (Position Statement)
- Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study 2022
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group 2023 (Guideline)
Disclaimer
This article is for general education and does not replace medical evaluation or laboratory-specific interpretation. Free light-chain results must be interpreted using the assay’s own reference range, kidney function, related monoclonal-protein tests, symptoms, and the full clinical picture. Do not assume that an abnormal kappa, lambda, or ratio result means cancer without review by a qualified clinician.
